Shintaro Azuma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shintaro Azuma has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Hisashi Hidaka
Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan
2 shared publicationsKazushi Numata
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
2 shared publicationsKoichiro Atsuda
Department of Pharmacy, Kitasato University Hospital, Sagamihara, Japan
2 shared publicationsMakoto Chuma
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan
2 shared publicationsMakoto Kako
Gastroenterology Medicine Center, Shonan Kamakura General Hospital, Kamakura, Japan
2 shared publicationsMasaaki Kondo
Department of Gastroenterology, Yokohama City University Hospital, Yokohama, Japan
2 shared publications
Latest Publications
- Open Access
- 27 March 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (5) , 223-234
Reporting Quality in Health Economic Evaluation Studies of Immune Checkpoint Inhibitors: A Systematic Review
Background and Objective The introduction of immune checkpoint inhibitors (ICIs) in oncology presents a critical healthcare policy challenge for resource allocation due to their substantial financial burden. This study assessed the reporting quality of health economic evaluation (HEE) studies of ICIs. Methods This study conducted a systematic literature search of four databases (PubMed, EMBASE, Cochrane CENTRAL, and the International HTA Database) for studies published between January 1, 2014 and December 31, 2022. All ICIs approved up to December 31, 2022, in the USA, EU, China, and Japan were included. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards published in 2013 (CHEERS 2013), which is the most widely recognised and implemented reporting guideline for HEE studies. Subgroup analyses were also performed based on the risk of sponsorship bias or citation of CHEERS 2013. Results A total of 5368 records were identified, 252 of which were included after full-text review. The study design, setting, and ICIs most frequently observed were cost-effectiveness and cost-utility analyses (63.5%), the USA (46.0%), and pembrolizumab (38.1%), respectively. Of the 24 items of CHEERS 2013, fully reported items were limited, particularly in the Methods section. Setting and location were not reported in 94.4% of the records. Subgroup analyses also revealed insufficient reporting of items in the Methods section, particularly “Setting and location”. Conclusion Health economic evaluation studies on ICIs between 2014 and 2022 had limited reporting across the 24 items of CHEERS 2013, regardless of sponsorship bias risk or citations. The items on setting and location in the Methods section were particularly underreported, emphasising the need for transparent reporting in HEE studies of ICIs.
- 27 March 2025
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 45 (5) , 223-234
Open AccessReporting Quality in Health Economic Evaluation Studies of Immune Checkpoint Inhibitors: A Systematic Review
Background and Objective The introduction of immune checkpoint inhibitors (ICIs) in oncology presents a critical healthcare policy challenge for resource allocation due to their substantial financial burden. This study assessed the reporting quality of health economic evaluation (HEE) studies of ICIs. Methods This study conducted a systematic literature search of four databases (PubMed, EMBASE, Cochrane CENTRAL, and the International HTA Database) for studies published between January 1, 2014 and December 31, 2022. All ICIs approved up to December 31, 2022, in the USA, EU, China, and Japan were included. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards published in 2013 (CHEERS 2013), which is the most widely recognised and implemented reporting guideline for HEE studies. Subgroup analyses were also performed based on the risk of sponsorship bias or citation of CHEERS 2013. Results A total of 5368 records were identified, 252 of which were included after full-text review. The study design, setting, and ICIs most frequently observed were cost-effectiveness and cost-utility analyses (63.5%), the USA (46.0%), and pembrolizumab (38.1%), respectively. Of the 24 items of CHEERS 2013, fully reported items were limited, particularly in the Methods section. Setting and location were not reported in 94.4% of the records. Subgroup analyses also revealed insufficient reporting of items in the Methods section, particularly “Setting and location”. Conclusion Health economic evaluation studies on ICIs between 2014 and 2022 had limited reporting across the 24 items of CHEERS 2013, regardless of sponsorship bias risk or citations. The items on setting and location in the Methods section were particularly underreported, emphasising the need for transparent reporting in HEE studies of ICIs.
- 21 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (7) , 884-889
Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital
- 21 March 2022
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 28 (7) , 884-889
Evaluation of a carbapenem antimicrobial stewardship program and clinical outcomes in a Japanese hospital
- Open Access
- 14 April 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1
Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 14 April 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1
Open AccessAuthor Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Open Access
- 13 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-11
Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
We investigated whether or not nitric oxide synthase 3 (NOS3) rs2070744 genotypes can affect the response for lenvatinib treatment in patients with hepatocellular carcinoma (HCC). We evaluated the relation of the NOS3 rs2070744 genotypes to the tumor response, progression-free survival (PFS), and overall survival (OS) as the response for lenvatinib. We also examined the association between fibroblast growth factor receptor (FGFR) gene polymorphisms, a potential feature of lenvatinib, and the response. There were no significant differences between the studies for either PFS or OS, even though patients with the TT genotype had a longer mean PFS (hazard ratio [HR] 0.60; p = 0.069) and mean OS (HR 0.46; p = 0.075) than those with the TC/CC genotypes. However, patients with a single-nucleotide polymorphism (SNP) combination pattern of the NOS3 rs2070744 TC/CC and FGFR4 rs351855 CT/TT genotypes had a significantly shorter mean PFS (HR 2.56; p = 0.006) and mean OS (HR 3.36; p = 0.013) than those with the other genotypes. The NOS3 rs2070744 genotypes did not influence the clinical response. However, the SNP combination pattern of the NOS3 rs2070744 and FGFR4 rs351855 genotypes may be helpful as treatment effect predictors and prognostic factors for HCC patients treated with lenvatinib.
- 13 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-11
Open AccessInfluence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
We investigated whether or not nitric oxide synthase 3 (NOS3) rs2070744 genotypes can affect the response for lenvatinib treatment in patients with hepatocellular carcinoma (HCC). We evaluated the relation of the NOS3 rs2070744 genotypes to the tumor response, progression-free survival (PFS), and overall survival (OS) as the response for lenvatinib. We also examined the association between fibroblast growth factor receptor (FGFR) gene polymorphisms, a potential feature of lenvatinib, and the response. There were no significant differences between the studies for either PFS or OS, even though patients with the TT genotype had a longer mean PFS (hazard ratio [HR] 0.60; p = 0.069) and mean OS (HR 0.46; p = 0.075) than those with the TC/CC genotypes. However, patients with a single-nucleotide polymorphism (SNP) combination pattern of the NOS3 rs2070744 TC/CC and FGFR4 rs351855 CT/TT genotypes had a significantly shorter mean PFS (HR 2.56; p = 0.006) and mean OS (HR 3.36; p = 0.013) than those with the other genotypes. The NOS3 rs2070744 genotypes did not influence the clinical response. However, the SNP combination pattern of the NOS3 rs2070744 and FGFR4 rs351855 genotypes may be helpful as treatment effect predictors and prognostic factors for HCC patients treated with lenvatinib.